NOAC stands for “new oral anticoagulant,” a term used to describe a class of blood-thinning medications that prevent blood clots. You may also see the acronym expanded as “novel oral anticoagulant.” Both versions refer to the same group of drugs, which work by directly blocking specific proteins in the clotting process. The preferred term in medical literature has shifted to DOAC, or “direct oral anticoagulant,” because these medications are no longer new and the word “direct” better describes how they actually work.
Why the Name Changed to DOAC
When these drugs first came to market, calling them “new” made sense. But as they’ve been in widespread use for over a decade, that label became misleading. The International Society of Thrombosis and Haemostasis now recommends the term DOAC instead, emphasizing the key feature that sets these drugs apart: they directly target specific clotting factors in the blood rather than working indirectly like older blood thinners. You’ll still see “NOAC” used frequently in hospitals, pharmacies, and online resources, and it refers to exactly the same medications.
The Four NOACs Available Today
There are four NOACs currently approved and in widespread use. They fall into two groups based on which part of the clotting process they block.
Three of them block a clotting protein called factor Xa, which plays a central role in forming blood clots:
- Apixaban (brand name Eliquis), taken twice daily
- Rivaroxaban (brand name Xarelto), taken once daily
- Edoxaban (brand name Savaysa), taken once daily
The fourth works differently, directly blocking thrombin, another key clotting protein:
- Dabigatran (brand name Pradaxa), taken twice daily
All four have a relatively short duration of action, with effects wearing off within roughly 12 hours. This is a significant difference from warfarin, which lingers in the body much longer.
What NOACs Are Used For
NOACs are prescribed for two broad purposes: preventing blood clots and treating ones that have already formed. The most common use is stroke prevention in people with atrial fibrillation, an irregular heart rhythm that allows blood to pool in the heart and form clots. These clots can travel to the brain and cause a stroke.
They’re also approved for treating deep vein thrombosis (blood clots in the legs) and pulmonary embolism (clots that travel to the lungs), as well as preventing these clots from coming back. Some NOACs are additionally used to prevent blood clots after hip or knee replacement surgery, a period when clot risk is elevated due to immobility and tissue damage.
How NOACs Differ From Warfarin
Before NOACs existed, warfarin was the standard oral blood thinner for decades. Warfarin works, but it comes with a significant practical burden. It requires regular blood tests, typically every few weeks, to check a value called the INR. Doctors use this number to keep warfarin’s effect within a narrow therapeutic window, usually an INR between 2.0 and 3.0. Too low and clots can still form; too high and dangerous bleeding becomes more likely. Warfarin also interacts with dozens of foods and medications, making dosing unpredictable.
NOACs eliminated most of that complexity. Their effects on the body are predictable enough that they can be prescribed at fixed doses without routine blood monitoring. They have far fewer interactions with food and other drugs. For people with atrial fibrillation, large clinical trials found that all four NOACs were at least as effective as warfarin at preventing strokes, and dabigatran at its higher dose was actually superior. Current guidelines in multiple countries now recommend NOACs over warfarin for most patients with atrial fibrillation and venous blood clots.
Reversal Agents for Emergencies
One early concern about NOACs was the lack of an antidote in case of serious bleeding. That gap has largely been closed. Dabigatran has a specific reversal agent called idarucizumab, a lab-made antibody fragment that binds to the drug and neutralizes it rapidly. For the factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban), a reversal agent called andexanet alfa is available.
The short half-life of NOACs also works in their favor during emergencies. Because the drugs wear off within roughly half a day, the bleeding risk drops relatively quickly even without a reversal agent, which is not the case with warfarin.
Who NOACs Are Not For
NOACs are specifically approved for “nonvalvular” atrial fibrillation, meaning they aren’t used in people whose irregular heartbeat is caused by certain types of heart valve disease, particularly mechanical heart valves. Those patients still require warfarin. People with severe kidney impairment may also need dose adjustments or may not be candidates for certain NOACs, since the kidneys play a role in clearing these drugs from the body.